Linked Data API

Show Search Form

Search Results

942538
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Lumacaftor/ivacaftor more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care what plans he has to ensure his Department continues to engage and meet with NHS England and Vertex to discuss access to Orkambi. more like this
tabling member constituency Thornbury and Yate more like this
tabling member printed
Luke Hall remove filter
uin 164468 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-07-20more like thismore than 2018-07-20
answer text <p>NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-07-20T10:09:26.39Zmore like thismore than 2018-07-20T10:09:26.39Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4450
label Biography information for Luke Hall more like this
942539
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Lumacaftor/ivacaftor more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether ensuring access to Orkambi for people with cystic fibrosis is a priority for his Department. more like this
tabling member constituency Thornbury and Yate more like this
tabling member printed
Luke Hall remove filter
uin 164469 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-07-20more like thismore than 2018-07-20
answer text <p>It is a key commitment of this Government to ensure that people with comparatively rarer conditions, like cystic fibrosis, get the same quality, safety and efficacy in medicines as those who have more common conditions.</p><p> </p><p>However, it is also necessary that Vertex prices Orkambi fairly and responsibly. That is why we must go through the right process with Vertex and NHS England, not the Government, working together to secure the best outcome for patients. NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p>
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-07-20T10:10:54.173Zmore like thismore than 2018-07-20T10:10:54.173Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4450
label Biography information for Luke Hall more like this
942540
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Lumacaftor/ivacaftor more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether a date has been set for the next meeting between NHS England and Vertex to discuss access to the drug Orkambi. more like this
tabling member constituency Thornbury and Yate more like this
tabling member printed
Luke Hall remove filter
uin 164470 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-07-20more like thismore than 2018-07-20
answer text <p>We are informed by NHS England that at the last meeting on 4 July, it was agreed that both parties would take time to reflect before a further meeting was arranged. NHS England has subsequently made a substantially increased proposal to Vertex and has offered to meet to discuss and clarify any aspects as required by the company.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-07-20T09:48:08.57Zmore like thismore than 2018-07-20T09:48:08.57Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4450
label Biography information for Luke Hall more like this
942541
registered interest false more like this
date remove filter
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Lumacaftor/ivacaftor more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what his Department's policy is on Vertex (a) waiving its confidentiality clause on the negotiations around NHS access to the drug Orkambi and (b) disclosing details of its offer to NHS England. more like this
tabling member constituency Thornbury and Yate more like this
tabling member printed
Luke Hall remove filter
uin 164471 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2018-07-20more like thismore than 2018-07-20
answer text <p>It is not in the Department’s gift to impose any requirement upon Vertex to waive its confidentiality clause or to disclose details of any offer in the negotiations around National Health Service access to the drug Orkambi. However, Ministers at the department have publicly urged Vertex to consider the offer made by NHS England and to waive confidentiality so that we can all see, in the interests of transparency, the kind of prices it is seeking to charge the NHS.</p> more like this
answering member constituency Winchester more like this
answering member printed Steve Brine more like this
question first answered
less than 2018-07-20T09:43:39.613Zmore like thismore than 2018-07-20T09:43:39.613Z
answering member
4067
label Biography information for Steve Brine more like this
tabling member
4450
label Biography information for Luke Hall more like this